We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and ... Syndax Pharmaceuticals Inc is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. Show more
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., May 3, 2024 WALTHAM, Mass., May 3, 2024 /PRNewswire/ -- Syndax...
Syndax to Announce First Quarter 2024 Financial Results and Host Conference Call and Webcast on May 8, 2024 PR Newswire WALTHAM, Mass., May 1, 2024 WALTHAM, Mass., May 1, 2024 /PRNewswire/...
Syndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum PR Newswire WALTHAM, Mass., April 10, 2024 WALTHAM, Mass., April 10, 2024 /PRNewswire/ --ย Syndax Pharmaceuticals...
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session PR Newswire WALTHAM, Mass., April 8, 2024...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., April 5, 2024 WALTHAM, Mass., April 5, 2024 /PRNewswire/ -- Syndax...
Syndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia PR Newswire WALTHAM, Mass., March 28, 2024 โ...
Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia PR Newswire WALTHAM, Mass., March 26, 2024 โ PDUFA action date set for...
Syndax Announces Appointment of Steven Closter as Chief Commercial Officer PR Newswire WALTHAM, Mass., March 18, 2024 โ Steven Closter brings more than 30 years of commercial experience in the...
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., March 1, 2024 WALTHAM, Mass., March 1, 2024 /PRNewswire/ -- Syndax...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.36 | 1.74842156387 | 20.59 | 23.04 | 20.475 | 1161745 | 21.55089936 | CS |
4 | -1.5 | -6.68151447661 | 22.45 | 23.325 | 20.13 | 898929 | 21.43739188 | CS |
12 | -1.21 | -5.46028880866 | 22.16 | 25.34 | 20.13 | 1098583 | 22.64047858 | CS |
26 | 6.03 | 40.4155495979 | 14.92 | 25.34 | 13.14 | 1315983 | 20.38437162 | CS |
52 | 0.97 | 4.85485485485 | 19.98 | 25.34 | 11.215 | 1302008 | 18.54238868 | CS |
156 | 4.78 | 29.5609152752 | 16.17 | 29.86 | 11.215 | 862842 | 19.41185759 | CS |
260 | 13.97 | 200.143266476 | 6.98 | 29.86 | 5.35 | 697100 | 18.87583039 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions